Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Polls

Editorial Advisory Board

Partners

Subscribe

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Articles

New study results show promise in dupilumab for bullous pemphigoid, with 59% of patients avoiding disease relapse.

Sanofi Reports High Efficacy in Dupilumab for BP

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

These positive data will support US regulatory submission by end of 2024.

Phase 3 LIBERTY-CUPID Study C Trial for Dupilumab Meets Primary, Secondary Endpoints for Chronic Spontaneous Urticaria

Swiss researchers found significant gender differences in melanoma care, including variations in information preferences and treatment decision-making.

Research Highlights Disparities in Melanoma Knowledge and Care

The review assessed infections, gastrointestinal AEs, blood and lymphatic disorders, and nervous system and musculoskeletal/connective tissue disorders.

Research Observe, Classify Adverse Event Profiles for Pediatric Patients Treated With JAK Inhibitors

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Twitter

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

View

DALLAS - Superficial chemical peels cannot turn back the clock, but they can offer a safe and effective rejuvenating procedure when used in appropriately selected patients and with proper technique, Seth L. Matarasso, M.D., said at the annual meeting of the American Society for Dermatologic Surgery.

Superficial Chemical Peels Retain Important Role Among Options